白念珠菌对唑类药物耐药机制的研究进展

doi:10.3969/j.issn.1673-8640.2014.09.025

检验医学 ›› 2014, Vol. 29 ›› Issue (9): 978-981.DOI: 10.3969/j.issn.1673-8640.2014.09.025

白念珠菌对唑类药物耐药机制的研究进展

魏冰¹,刘锦燕²,史册¹,项明洁²

1. 上海交通大学医学院附属瑞金医院检验科,上海 200025;
2. 上海交通大学医学院附属瑞金医院卢湾分院放免检验科,上海 200020

收稿日期:2013-10-12 出版日期:2014-09-30 发布日期:2014-09-25
通讯作者: 项明洁,联系电话:021-63867643
作者简介:魏冰,女,1986年生,硕士,技师,主要从事白念珠菌的耐药机制研究
基金资助:
上海市卫生局资助项目(2009239);上海市科委生物医药资助项目(11411960500);上海市医学重点专科建设项目(2012年A类21号)

Research advances on the mechanisms for Candida albicans resistance to antifungal azole

WEI Bing¹, LIU Jinyan², SHI Ce¹, XIANG Mingjie²

1. Department of Clinical Laboratory, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China;
2. Department of Radioimmunology and Clinical Laboratory, Luwan Branch, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200020, China

Received:2013-10-12 Online:2014-09-30 Published:2014-09-25

摘要/Abstract

摘要： 白念珠菌是临床最常见的条件致病性真菌,由于抗真菌药物的长期滥用,其对唑类药物的耐药逐年增多,耐药现象已经成为药物治疗的难点。目前,白念珠菌对唑类药物耐药的主要机制包括:ERG11基因突变或过度表达导致的靶位酶的改变、多药转运蛋白过度表达、细胞应激反应和生物膜的形成等。现就白念珠菌对唑类药物的耐药机制作简单归纳。

关键词: 白念珠菌, 唑类药物, 耐药机制, 靶酶, 多药转运蛋白, 生物膜

Abstract: Candida albicans is the most important opportunistic pathogenic yeast in clinic. With the widespread use of antifungal agents, the chance of antifungal resistance in Candida albicans is increasing. The emergence of resistance is an difficult point for drug treatment. Mutation or overexpression in drug target enzymes, overexpression of multidrug transporters, cellular stress responses, formation of biofilm and so on, compose the major molecular mechanisms which contribute to the development of antifungal azole resistance in Candida albicans. This paper gives a general review of the azole resistance mechanisms in Candida albians.

Key words: Candida albicans, Azole, Resistance mechanism, Target enzyme, Multidrug transporter, Biofilm

中图分类号:

R446.5

魏冰,刘锦燕,史册,项明洁. 白念珠菌对唑类药物耐药机制的研究进展[J]. 检验医学, 2014, 29(9): 978-981.

WEI Bing, LIU Jinyan, SHI Ce, XIANG Mingjie. Research advances on the mechanisms for Candida albicans resistance to antifungal azole[J]. , 2014, 29(9): 978-981.

参考文献

[1] Perea S, Patterson TF. Antifungal resistance in pathogenic fungi [J].Clin Infect Dis, 2002,35(9):1073-1080.
[2] 曹先伟,冀朝辉,万喆,等.白念珠菌耐药株CYP 51基因突变热点探讨[J].中华医院感染学杂志, 2004, 14(11):1215-1218.
[3] White TC. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans[J].Antimicrob Agents Chemother, 1997,41(7): 1488-1494.
[4] Müller TC, Rocha JB, Morsch VM, et al. Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity[J].Biochim Biophys Acta, 2002,1587(1): 92-98.
[5] Kontoyiannis DP,Sagar N,Hirschi KD.Overexpression of Erg11 p by the regulatable GAL1 promoter confers fluconazole resistance in Saccharomyces cerevisiae[J]. Antimicrob Agents Chemother, 1999, 43(11): 2798-2800.
[6] MacPherson S, Akache B, Weber S, et al.Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes[J].Antimicrob Agents Chemother, 2005,49(5):1745-1752.
[7] Hoehamer CF, Cummings ED, Hilliard GM, et al. Upc2p-associated differential protein expression in Candida albicans[J].Proteomics, 2009, 9(20):4726-4730.
[8] Heilmann CJ, Schneider S, Barker KS, et al. An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans[J].Antimicrob Agents Chemother,2010,54(1):353-359.
[9] Lyons CN, White TC.Transcriptional analyses of antifungal drug resistance in Candida albicans[J].Antimicrob Agents Chemother, 2000,44(9):2296-2303.
[10] Cowen LE, Kohn LM, Anderson JB. Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans[J].J Bacteriol, 2001,183(10):2971-2978.
[11] Coste A,Selmecki A,Forche A,et al.Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates[J].Eukaryot Cell,2007,6(10):1889-1904.
[12] Coste A, Turner V, Ischer F,et al.A mutation in Tac1p,a trainscription factor regulating CDR1 and CDR2,is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans[J].Genetics,2006,172(4):2139-2156.
[13] Coste AT, Crittin J, Bauser C, et al. Functional analysis of cis- and trans- acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system[J].Eukaryot Cell, 2009, 8(8):1250-1267.
[14] Morschhuser J.Regulation of multidrug resistance in pathogenic fungi[J]. Fungal Genet Biol,2010,47(2):94-106.
[15] Talibi D, Raymond M. Isolation of a putative Candida albicans transcriptional regulator involved in pleiotropic drug resistance by functional complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiae[J].J Bacteriol, 1999,181(1):231-240.
[16] Schubert S, Rogers PD, Morschhuser J.Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains[J]. Antimicrob Agents Chemother, 2008, 52(12):4274-4280.
[17] Dunkel N, Blass J, Rogers PD, et al. Mutations in the multi-drug resistance regulator MRR1,followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains[J]. Mol Microbiol, 2008, 69(4):827-840.
[18] Liu TT, Znaidi S, Barker KS, et al. Genome-wide expression and location analyses of the Candida albicans Tac1p regulon[J].Eukaryot Cell, 2007, 6(11):2122-2138.
[19] Karababa M, Valentino E, Pardini G, et al. CRZ1, a target of the calcineurin pathway in Candida albicans[J].Mol Microbiol, 2006, 59(5):1429-1451.
[20] Nett JE, Sanchez H, Cain MT, et al. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan [J]. J Infect Dis, 2010, 202(1):171-175.
[21] Khot PD, Suci PA, Miller RL, et al. A small subpopulation of blastospores in Candida albicans biofilms exhibit resistance to amphotericin B associated with differential regulation of ergosterol and beta-1, 6-glucan pathway genes [J]. Antimicrob Agents Chemother, 2006, 50(11): 3708-3716.
[22] Lepak A, Nett J, Lincoln L, et al. Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole [J]. Antimicrob Agents Chemother, 2006, 50(4):1311-1319.
[23] García-Snchez S, Aubert S, Iraqui I, et al. Candida albicans biofilms: a developmental state associated with specific and stable gene expression patterns [J]. Eukaryot Cell, 2004, 3(2): 536-545.
[24] 赵亮,陈贻锴. 生物膜结构对白色念珠菌的耐药性的影响[J]. 医学综述,2007, 13 (12): 889-891.

白念珠菌对唑类药物耐药机制的研究进展

Research advances on the mechanisms for Candida albicans resistance to antifungal azole

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	孙伟, 夏帅, 樊玉健, 马立艳. 不同基因型别纹带棒状杆菌耐药特点和生物膜形成能力分析[J]. 检验医学, 2022, 37(6): 505-509.
[2]	张亚茹, 凌丽燕, 陈敏. EUCAST和CLSI微量肉汤稀释法白念珠菌体外药物敏感性试验结果比较[J]. 检验医学, 2022, 37(10): 974-978.
[3]	王立新, 苏云福, 王毅. 临床病原菌磷霉素耐药机制研究进展[J]. 检验医学, 2022, 37(10): 993-997.
[4]	张冠怡, 姚冬婷, 王健, 胡晓波. 光滑念珠菌耐药机制及中西药治疗光滑念珠菌感染研究进展[J]. 检验医学, 2021, 36(7): 761-765.
[5]	周燕霞, 金东芳. 单宁酸抑制肺炎克雷伯菌生物膜形成的作用及其机制[J]. 检验医学, 2021, 36(10): 1070-1073.
[6]	李婵婵, 王茹, 罗文英. 铜绿假单胞菌转录因子PsrA全局调控研究进展[J]. 检验医学, 2020, 35(8): 832-836.
[7]	李贞, 殷红梅, 陈伟琴, 薛赢俊, 胡骏, 诸斌, 胡晓波. 土槿皮乙酸与氟康唑联合应用于体外抗白念珠菌活性研究[J]. 检验医学, 2020, 35(7): 663-667.
[8]	张秋, 李杰, 王猛, 王毅, 杨波, 胡征. 嗜肺军团菌快速检测胶体金试纸的研制[J]. 检验医学, 2020, 35(7): 726-733.
[9]	王姜琳, 孙杰, 杨慧健, 王冰洁, 潘芬, 张泓. 儿童耐氨苄西林流感嗜血杆菌耐药机制及同源性研究[J]. 检验医学, 2020, 35(6): 513-518.
[10]	钟峰, 冯艺, 张晶晶, 许岩, 方咏梅, 陶秀彬, 吴竞. 替加环素联合亚胺培南对黏液型铜绿假单胞菌的体外抗菌活性及生物膜抑制作用分析[J]. 检验医学, 2020, 35(6): 519-523.
[11]	孙康德, 张家胜, 陈旭, 虞中敏, 陈福祥. 口腔白念珠菌耐药性及毒力因子表达水平相关性研究[J]. 检验医学, 2019, 34(8): 730-735.
[12]	张心宇, 杜雪飞, 邹桂玲, 姜晓峰. 鲍曼不动杆菌对替加环素耐药机制研究进展[J]. 检验医学, 2019, 34(7): 656-660.
[13]	李巍, 艾芙琪, 马逸珉, 王蓓, 田月如. 携带bla_NDM-1碳青霉烯类耐药雷极普罗威登斯菌耐药机制研究[J]. 检验医学, 2019, 34(1): 67-70.
[14]	徐炜新, 孙杰. 多位点序列分析法在白念珠菌性阴道炎唑类耐药菌株分子流行病学研究中的运用[J]. 检验医学, 2018, 33(3): 233-238.
[15]	莫芊芊综述, 莫甲光审校. sRNA调控生物膜形成与细菌耐药性的相关性研究进展[J]. 检验医学, 2017, 32(6): 549-552.